Creative Medical Technology (CELZ) vs Liminatus Pharma (LIMN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Creative Medical Technology is the larger company by market cap ($6.5 million vs $4.9 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CELZ | LIMN |
|---|---|---|
| Share price | $0.85 | $3.63 |
| Market cap | $6.45M | $4.88M |
| 1-day change | -1.20% | -1.63% |
| EPS (TTM) | $-2.07 | $-23.50 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.25 | $141.50 |
| 52-week low | $0.62 | $3.29 |
| Distance from 52-week high | -86.40% | -97.43% |
| Analyst consensus | none | — |
| Avg. price target upside | +2252.94% | — |
| Average volume | 6.77M | 453.28K |
| Shares outstanding | 7.59M | 1.34M |
| Employees | 4 | 1 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Creative Medical Technology
CELZ stock →Creative Medical Technology Holdings, Inc., a commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction, and FemCelz for the treatment of loss of genital sensitivity and dryness.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 4 employees
About Liminatus Pharma
LIMN stock →Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 1 employees
CELZ vs LIMN FAQ
Which is bigger, Creative Medical Technology or Liminatus Pharma?
Creative Medical Technology (CELZ) is larger, with a market capitalization of $6.45M compared with $4.88M for Liminatus Pharma (LIMN).
Are Creative Medical Technology and Liminatus Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.